Premium
Potentiation of lysis of leukaemia cells by a bispecific antibody to CD33 and CD16 (FcγRIII) expressed by human natural killer (NK) cells
Author(s) -
Silla Lucia M. R.,
Chen Jian,
Zhong Ruikun,
Whiteside Theresa L.,
Ball Edward D.
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb08406.x
Subject(s) - cd16 , bispecific antibody , immunology , natural killer cell , antibody , biology , cytotoxicity , immune system , monoclonal antibody , in vitro , cd3 , genetics , cd8
Bispecific antibodies recognizing tumour‐associated antigens and trigger molecules expressed on immune effector cells have been shown to redirect cytotoxicity of several types of peripheral blood cells against relevant tumour targets. Among various effector cells, natural killer (NK) cells appear to play a role in defence against leukaemia. Here we report the successful chemical conjugation of monoclonal antibodies to CD33 and CD16 to create a bispecific antibody (BsAb 251x3G8). This bispecific antibody is capable of augmenting the killing of otherwise resistant leukaemia cells by peripheral blood lymphocytes (PBL), purified resting NK (R‐NK) cells, and activated NK (A‐NK) cells. BsAb 251x3G8 may play a role in the therapy of acute myeloid leukaemia (AML) through redirecting the cytotoxic activity of endogenous or adoptively transferred NK cells.